SG11202104121QA - Methods for synthesis of radionuclide complex - Google Patents

Methods for synthesis of radionuclide complex

Info

Publication number
SG11202104121QA
SG11202104121QA SG11202104121QA SG11202104121QA SG11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA
Authority
SG
Singapore
Prior art keywords
synthesis
methods
radionuclide complex
radionuclide
complex
Prior art date
Application number
SG11202104121QA
Inventor
Lorenza Fugazza
Palo Francesco De
Donato Barbato
Maurizio F Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Italy Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl filed Critical Advanced Accelerator Applications Italy Srl
Publication of SG11202104121QA publication Critical patent/SG11202104121QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202104121QA 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex SG11202104121QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/079909 WO2020088767A1 (en) 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex

Publications (1)

Publication Number Publication Date
SG11202104121QA true SG11202104121QA (en) 2021-05-28

Family

ID=64083105

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104121QA SG11202104121QA (en) 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex

Country Status (11)

Country Link
US (3) US20200131224A1 (en)
EP (1) EP3873874A1 (en)
JP (2) JP2022516814A (en)
KR (1) KR20210086637A (en)
CN (1) CN112969675A (en)
AU (1) AU2018447938A1 (en)
BR (1) BR112021007851A2 (en)
CA (1) CA3159337A1 (en)
IL (1) IL282701A (en)
SG (1) SG11202104121QA (en)
WO (2) WO2020088767A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN116528904A (en) 2020-08-27 2023-08-01 普罗博开发商业中心 Radiopharmaceuticals and methods
EP4208468A1 (en) * 2020-09-03 2023-07-12 Curium US LLC Radiolabeling and formulation for scale up of 64cu-dotatate
CN114685608B (en) * 2020-12-29 2023-10-20 北京大学深圳研究生院 Cyclic peptide compound containing trithiophene bond or derivative thereof, synthesis method and application thereof
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
IT202100024377A1 (en) * 2021-09-22 2023-03-22 Scogif S R L AUTOMATIC EQUIPMENT FOR THE SYNTHESIS OF PEPTIDE-BASED RADIO-PHARMACEUTICALS FOR DIAGNOSTIC AND/OR THERAPEUTIC USE
WO2023148680A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
US20230248853A1 (en) * 2022-02-04 2023-08-10 Westinghouse Electric Company Llc Method and device for direct production of radio-isotope based cancer treatment pharmaceuticals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855509B1 (en) * 2015-11-12 2018-05-09 한국원자력연구원 Vial kit for manufacturing radiopharmaceutical and manufacturing method for using the same

Also Published As

Publication number Publication date
AU2018447938A1 (en) 2021-05-13
CN112969675A (en) 2021-06-15
US20200131224A1 (en) 2020-04-30
IL282701A (en) 2021-06-30
CA3159337A1 (en) 2020-05-07
WO2020088767A1 (en) 2020-05-07
KR20210086637A (en) 2021-07-08
US20220041649A1 (en) 2022-02-10
JP2023178388A (en) 2023-12-14
BR112021007851A2 (en) 2021-08-03
JP2022516814A (en) 2022-03-02
WO2020089379A1 (en) 2020-05-07
US20210316019A1 (en) 2021-10-14
EP3873874A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
IL282701A (en) Methods for synthesis of radionuclide complex
IL292754A (en) Method of synthesis
IL255817B (en) Synthesis of heterocyclic compounds
IL262659B (en) Synthesis of indazoles
SG10202111790YA (en) Synthesis of omecamtiv mecarbil
IL262413B (en) Synthesis of indazoles
GB201801768D0 (en) Synthesis method
HK1250719A1 (en) Synthesis of desosamines
GB201701396D0 (en) Novel alternating-phase synthesis method
GB201710241D0 (en) New route of synthesis for opicapone
PT3368513T (en) Process for the synthesis of pirfenidone
PT3759082T (en) Process for the synthesis of 6-chloromethyluracil
EP3792296C0 (en) Method for the synthesis of polyethers
GB201903055D0 (en) Method of oligonucleaotide synthesis
GB201804905D0 (en) Cataltic synthesis of biarylic compounds
GB201807468D0 (en) Methods of synthesis
GB201917499D0 (en) Methods of synthesis
GB201809404D0 (en) Method of synthesis
SG11202011378WA (en) Synthesis of tipifarnib
GB201820685D0 (en) Synthesis of 8-chloroadenosine derivatives
GB201805283D0 (en) Method of synthesizing a radiopharmaceutical
PL3713939T3 (en) Improved process for the synthesis of linker-drug vc-seco
GB201523222D0 (en) Levosimendan medicine intermediate for acetaminophen acetone synthesis method
SI3320102T1 (en) Method for the synthesis of pentostatin